Login to Your Account



NGM Bio touts liver fat reductions in phase II

By Michael Fitzhugh
Staff Writer

Monday, April 24, 2017

AMSTERDAM – NGM Biopharmaceuticals Inc. honed in on the liver de-fatting feats of its lead candidate, NGM282, during a presentation at the International Liver Conference.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription